FDA approves Xarelto to reduce risk of blood clots after hip, knee replacements

Posted by Food and Drug Administration--Press Releases on Tuesday Jul 5, 2011 Under News

On July 1, the U.S. Food and Drug Administration approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.

Be Sociable, Share!

Comments are closed.